ICON public limited company is a contract research organization (CRO), which is engaged in providing outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company is engaged in the strategic development, management and analysis of programs that support the various stages of the clinical development process, from compound selection to Phase I-IV clinical studies. Its services include clinical trials management, biometric activities, consulting, imaging, contract staffing, informatics and laboratory services. The Company's information systems offerings include ICONIK, Firecrest, ADDPLAN, AptivAdvantage and Aptiv Insite. It conducts various laboratory tests on the patient's blood, urine and other bodily fluids at appropriate intervals during the trial. The Company offers clinical development services, including investigator recruitment, patient registries, outcomes research, clinical data management, immunoassay development and others.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology & Medical Research
- Sub-Industry: N/A
- Symbol: NASDAQ:ICLR
- CUSIP: N/A
- Web: www.iconplc.com
- Market Cap: $5.99693 billion
- Outstanding Shares: 54,041,000
- 50 Day Moving Avg: $108.70
- 200 Day Moving Avg: $93.99
- 52 Week Range: $73.76 - $117.53
Sales & Book Value:
- Trailing P/E Ratio: 22.51
- Foreward P/E Ratio: 18.78
- P/E Growth: 1.50
- Annual Revenue: $1.72 billion
- Price / Sales: 3.49
- Book Value: $19.05 per share
- Price / Book: 5.83
- EBIDTA: $393.57 million
- Net Margins: 15.97%
- Return on Equity: 28.72%
- Return on Assets: 15.01%
- Debt-to-Equity Ratio: 0.34%
- Current Ratio: 2.11%
- Quick Ratio: 2.11%
- Average Volume: 346,255 shs.
- Beta: 0.61
- Short Ratio: 3.49
Frequently Asked Questions for ICON PLC (NASDAQ:ICLR)
What is ICON PLC's stock symbol?
ICON PLC trades on the NASDAQ under the ticker symbol "ICLR."
How were ICON PLC's earnings last quarter?
ICON PLC (NASDAQ:ICLR) announced its quarterly earnings data on Thursday, July, 27th. The company reported $1.31 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $1.30 by $0.01. The firm earned $431 million during the quarter, compared to analysts' expectations of $430.68 million. ICON PLC had a return on equity of 28.72% and a net margin of 15.97%. The company's quarterly revenue was up 5.0% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.14 EPS. View ICON PLC's Earnings History.
When will ICON PLC make its next earnings announcement?
What guidance has ICON PLC issued on next quarter's earnings?
ICON PLC issued an update on its FY17 earnings guidance on Thursday, July, 27th. The company provided EPS guidance of $5.18-5.36 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $5.18. The company issued revenue guidance of $1.74-1.77 billion, compared to the consensus revenue estimate of $1.72 billion.
Where is ICON PLC's stock going? Where will ICON PLC's stock price be in 2017?
10 analysts have issued 12 month price objectives for ICON PLC's shares. Their predictions range from $92.00 to $128.00. On average, they expect ICON PLC's share price to reach $111.50 in the next year. View Analyst Ratings for ICON PLC.
Are investors shorting ICON PLC?
ICON PLC saw a increase in short interest during the month of August. As of August 31st, there was short interest totalling 1,264,346 shares, an increase of 30.4% from the August 15th total of 969,335 shares. Based on an average daily volume of 324,873 shares, the short-interest ratio is currently 3.9 days. Currently, 2.4% of the company's shares are sold short.
Who are some of ICON PLC's key competitors?
Some companies that are related to ICON PLC include Alnylam Pharmaceuticals (ALNY), Alkermes PLC (ALKS), Seattle Genetics (SGEN), Qiagen N.V. (QGEN), Ionis Pharmaceuticals (IONS), Exact Sciences Corporation (EXAS), INC Research Holdings (INCR), Galapagos NV (GLPG), Charles River Laboratories International (CRL), United Therapeutics Corporation (UTHR), PRA Health Sciences (PRAH), ACADIA Pharmaceuticals (ACAD), Bio-Techne Corp (TECH), PAREXEL International Corporation (PRXL), FibroGen (FGEN), Puma Biotechnology (PBYI), Nektar Therapeutics (NKTR) and WuXi PharmaTech (Cayman) (WX).
Who are ICON PLC's key executives?
ICON PLC's management team includes the folowing people:
- Ciaran Murray, Chairman of the Board
- Steve Cutler, Chief Executive Officer, Director
- Brendan Brennan, Chief Financial Officer
- Diarmaid Cunningham, Executive Vice President, General Counsel, Secretary
- Hugh Brady, Non-Executive Director
- John Climax, Non-Executive Director
- William W. Hall M.D., Ph.D., Non-Executive Director
- Ronan Lambe Ph.D., Non-Executive Director
- Mary K. Pendergast J.D., Non-Executive Director
Who owns ICON PLC stock?
ICON PLC's stock is owned by a variety of of institutional and retail investors. Top institutional investors include WCM Investment Management CA (7.34%), Earnest Partners LLC (5.16%), Alliancebernstein L.P. (5.07%), FMR LLC (4.24%), Acadian Asset Management LLC (4.07%) and Wasatch Advisors Inc. (3.42%). View Institutional Ownership Trends for ICON PLC.
Who sold ICON PLC stock? Who is selling ICON PLC stock?
ICON PLC's stock was sold by a variety of institutional investors in the last quarter, including Earnest Partners LLC, Lord Abbett & CO. LLC, Neuberger Berman Group LLC, Alliancebernstein L.P., Balyasny Asset Management LLC, Westfield Capital Management Co. LP, Kennedy Capital Management Inc. and Arrowstreet Capital Limited Partnership. View Insider Buying and Selling for ICON PLC.
Who bought ICON PLC stock? Who is buying ICON PLC stock?
ICON PLC's stock was purchased by a variety of institutional investors in the last quarter, including Koch Industries Inc., FMR LLC, Janus Henderson Group PLC, Mckinley Capital Management LLC Delaware, WCM Investment Management CA, Systematic Financial Management LP, Renaissance Technologies LLC and Canada Pension Plan Investment Board. View Insider Buying and Selling for ICON PLC.
How do I buy ICON PLC stock?
Shares of ICON PLC can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is ICON PLC's stock price today?
MarketBeat Community Rating for ICON PLC (NASDAQ ICLR)MarketBeat's community ratings are surveys of what our community members think about ICON PLC and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of ICON PLC stock can currently be purchased for approximately $110.97.
Consensus Ratings for ICON PLC (NASDAQ:ICLR) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||2 Hold Ratings, 7 Buy Ratings, 1 Strong Buy Rating|
|Consensus Rating:||Buy (Score: 2.90)|
|Consensus Price Target: ||$111.50 (0.48% upside)|
Analysts' Ratings History for ICON PLC (NASDAQ:ICLR)
(Data available from 9/24/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|9/12/2017||Jefferies Group LLC||Reiterated Rating||Buy||$122.00||Low|
|9/11/2017||Bank of America Corporation||Initiated Coverage||Buy -> Buy||$128.00||Low|
|7/31/2017||SunTrust Banks, Inc.||Upgrade||Hold -> Buy||$93.00 -> $126.00||Medium|
|7/28/2017||Credit Suisse Group||Reiterated Rating||Buy||Low|
|7/27/2017||Mizuho||Boost Price Target||Neutral -> Neutral||$104.00 -> $108.00||Low|
|7/7/2017||Goldman Sachs Group, Inc. (The)||Upgrade||Buy -> Conviction-Buy||$117.00||High|
|6/9/2017||Robert W. Baird||Lower Price Target||Outperform||$107.00 -> $97.00||Low|
|4/28/2017||Evercore ISI||Boost Price Target||Outperform||$91.50 -> $92.00||Low|
|10/20/2016||Avondale Partners||Upgrade||Underperform -> Market Perform||N/A|
Earnings History for ICON PLC (NASDAQ:ICLR)Earnings History by Quarter for ICON PLC (NASDAQ ICLR)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|7/27/2017||6/30/2017||$1.30||$1.31||$430.68 million||$431.00 million||View||N/A|
|4/27/2017||3/31/2017||$1.27||$1.29||$432.21 million||$432.00 million||View||N/A|
|2/16/2017||Q416||$1.26||$1.33||$440.78 million||$435.00 million||View||Listen|
|10/20/2016||Q316||$1.18||$1.19||$420.14 million||$420.20 million||View||Listen|
|7/26/2016||Q216||$1.14||$1.14||$409.97 million||$411.00 million||View||Listen|
|4/26/2016||Q116||$1.11||$1.12||$414.35 million||$400.50 million||View||Listen|
|2/23/2016||Q415||$1.10||$1.11||$409.42 million||$403.00 million||View||Listen|
|10/27/2015||Q315||$1.01||$1.02||$399.02 million||$394.70 million||View||Listen|
|7/28/2015||Q215||$0.90||$0.95||$402.15 million||$389.00 million||View||Listen|
|4/28/2015||Q115||$0.81||$0.90||$391.11 million||$388.00 million||View||N/A|
|2/25/2015||Q4||$0.76||$0.87||$391.37 million||$390.10 million||View||N/A|
|10/22/2014||Q314||$0.70||$0.79||$391.12 million||$388.00 million||View||Listen|
|7/30/2014||Q2||$0.58||$0.64||$376.89 million||$376.00 million||View||Listen|
|4/30/2014||Q1||$0.50||$0.57||$352.14 million||$350.00 million||View||Listen|
|2/20/2014||Q413||$0.45||$0.53||$339.86 million||$345.00 million||View||Listen|
|10/24/2013||Q313||$0.41||$0.45||$332.58 million||$339.80 million||View||Listen|
|7/25/2013||Q2 2013||$0.38||$0.43||$321.82 million||$334.20 million||View||Listen|
|4/25/2013||Q1 2013||$0.34||$0.36||$300.81 million||$317.00 million||View||Listen|
|2/19/2013||Q4 2012||$0.33||$0.34||$291.96 million||$300.00 million||View||Listen|
|11/1/2012||Q312||$0.27||$0.29||$282.67 million||$286.00 million||View||N/A|
Earnings Estimates for ICON PLC (NASDAQ:ICLR)
2017 EPS Consensus Estimate: $5.28
2018 EPS Consensus Estimate: $5.80
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for ICON PLC (NASDAQ:ICLR)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for ICON PLC (NASDAQ:ICLR)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for ICON PLC (NASDAQ:ICLR)
Latest Headlines for ICON PLC (NASDAQ:ICLR)
ICON PLC (ICLR) Chart for Sunday, September, 24, 2017